Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion is a promising healthcare technology company with a strong proprietary technology and a growing customer base, as reflected in its solid Q1 FY26 revenue and EPS beats. While increased operating expenses could potentially affect its bottom line, the recent addition of new commercial agreements and a senior hire demonstrate a strong marketing push. With a growing patent portfolio, ongoing clinical trials, and a healthy balance sheet, Aclarion appears well-positioned for long-term success in the healthcare market.

Bears say

Aclarion is undergoing a CLARITY trial in Q4 2026 to provide supportive data for Nociscan's efficacy in improving surgical outcomes for chronic low back pain. However, the company's revenue sources are limited to one product and are solely based on contracts in the US, which poses a substantial risk for financial stability. With the interim data expected in 2026, the company's future financial performance and success will be heavily dependent on the success of the trial and market adoption of Nociscan.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.